Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patie ...

While low-density lipoprotein (LDL) particles are much more abundant than lipoprotein(a) [Lp(a)] particles and carry the greatest overall risk for coronary heart disease (CHD), on a per-particle basis ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...